Addressing Clinical Inertia
in CKD & Heart Failure
Through Enhanced Knowledge
of CKD & Heart Failure
"Clinicians often stop RAASi therapy in the presence of mild or moderate hyperkalemia. While the potassium may initially come down, you have now exchanged a short- term risk for a long-term risk. Potassium binders are enablers. They enable you to do what you know is right, per guidelines, and give therapy that will help the kidney and the heart improve function."
— George Bakris, MD, and Javed Butler, MD
Steering Committee Co-Chairs
Welcome to Addressing Clinical Inertia in CKD
& Heart Failure Management
This NEW CME series takes a look at the challenges facing healthcare professionals involved in the care of patients with CKD and HF. After learning about the latest guideline recommendations and clinical trial data, participants will be able to translate this advancing knowledge into clinical practice to increase the number of patients with CKD and HF receiving the most appropriate, optimal therapy.
Check out the Featured Programs below and stay tuned for new programs launching this year.
Explore our CME Curriculum on Chronic Kidney Disease & Heart Failure for Guideline-Recommended Treatment Options & Take a Deep Dive Into the Importance of Maintaining RAASi Therapy
VOICES OF THE